Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Galustian

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
BJU International|July 6, 2013
Tools to investigate biomarker expression in bladder cancer progressionChristine Galustian
Future Oncology (London, England)|October 6, 2010
The potential of immunomodulatory drugs in the treatment of solid tumorsAngus Dalgleish, Christine Galustian
Expert Opinion on Pharmacotherapy|February 25, 2009
Lenalidomide: a novel anticancer drug with multiple modalitiesChristine Galustian, Angus Dalgleish
Cancer Informatics|March 18, 2010
The power of the web in cancer drug discovery and clinical trial design: research without a laboratory?Christine Galustian, Angus G Dalgleish
Oncoimmunology|July 9, 2015
Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A reviewSandeep Nayar, Prokar Dasgupta, Christine Galustian
BJU International|July 2, 2016
Immune checkpoint blockade - a treatment for urological cancers?Oussama Elhage, Christine Galustian, Prokar Dasgupta
Frontiers in Oncology|March 29, 2021
Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate CancerAna M Esteves, Efthymia Papaevangelou, Prokar Dasgupta, et al.
Cytokine & Growth Factor Reviews|April 13, 2016
HES1 in immunity and cancerAradhana Rani, Roseanna Greenlaw, Richard A Smith, et al.
Apoptosis : an International Journal on Programmed Cell Death|November 24, 2011
The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeuticsCarole Brosseau, Kay Colston, Angus George Dalgleish, et al.
Frontiers in Immunology|July 19, 2023
Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse modelsEfthymia Papaevangelou, Ana M Esteves, Prokar Dasgupta, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
BJU International|July 6, 2013
Tools to investigate biomarker expression in bladder cancer progressionChristine Galustian
Future Oncology (London, England)|October 6, 2010
The potential of immunomodulatory drugs in the treatment of solid tumorsAngus Dalgleish, Christine Galustian
Expert Opinion on Pharmacotherapy|February 25, 2009
Lenalidomide: a novel anticancer drug with multiple modalitiesChristine Galustian, Angus Dalgleish
Cancer Informatics|March 18, 2010
The power of the web in cancer drug discovery and clinical trial design: research without a laboratory?Christine Galustian, Angus G Dalgleish
Oncoimmunology|July 9, 2015
Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A reviewSandeep Nayar, Prokar Dasgupta, Christine Galustian
BJU International|July 2, 2016
Immune checkpoint blockade - a treatment for urological cancers?Oussama Elhage, Christine Galustian, Prokar Dasgupta
Frontiers in Oncology|March 29, 2021
Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate CancerAna M Esteves, Efthymia Papaevangelou, Prokar Dasgupta, et al.
Cytokine & Growth Factor Reviews|April 13, 2016
HES1 in immunity and cancerAradhana Rani, Roseanna Greenlaw, Richard A Smith, et al.
Apoptosis : an International Journal on Programmed Cell Death|November 24, 2011
The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeuticsCarole Brosseau, Kay Colston, Angus George Dalgleish, et al.
Frontiers in Immunology|July 19, 2023
Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse modelsEfthymia Papaevangelou, Ana M Esteves, Prokar Dasgupta, et al.
Pageof 4